SAN DIEGO, Feb. 23, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today reported new positive clinical data from a Phase II Investigator Sponsored Trial assessing the combination of OncoSec's investigational intratumoral therapy, ImmunoPulse® IL-12, and the approved anti-PD- 1 therapy (pembrolizumab), in patients with unresectable metastatic melanoma. The results of this single-arm, open-label trial, which was led by the University of California, San Francisco (UCSF), indicated that ImmunoPulse® IL-12 can increase response rates in patients who are not expected to respond to anti-PD-1 therapy alone.
